BR112022022932A2 - Inibidor de vcp/p97 para o tratamento do câncer - Google Patents

Inibidor de vcp/p97 para o tratamento do câncer

Info

Publication number
BR112022022932A2
BR112022022932A2 BR112022022932A BR112022022932A BR112022022932A2 BR 112022022932 A2 BR112022022932 A2 BR 112022022932A2 BR 112022022932 A BR112022022932 A BR 112022022932A BR 112022022932 A BR112022022932 A BR 112022022932A BR 112022022932 A2 BR112022022932 A2 BR 112022022932A2
Authority
BR
Brazil
Prior art keywords
vcp
inhibitors
cancer treatment
subject
cancer
Prior art date
Application number
BR112022022932A
Other languages
English (en)
Inventor
Jain Stuart Monic
Le Moigne Ronan
James Anderson Daniel
Rolfe Mark
Lakshmi Rajangam Kanya
Nicholas Djakovic Stevan
Daniel Vargas Jesse
Original Assignee
Cleave Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleave Therapeutics Inc filed Critical Cleave Therapeutics Inc
Publication of BR112022022932A2 publication Critical patent/BR112022022932A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INIBIDOR DE VCP/p97 PARA O TRATAMENTO DE CÂNCER. São descritos neste documento métodos de tratamento de câncer em um sujeito em necessidade, compreendendo administrar ao sujeito uma composição farmacêutica compreendendo 1-(4-(benzilamino)-5,6,7,8-tetrahidropirido[2,3-d]pirimidin-2 -il)-2-metil-1H-indol-4-carboxamida, ou um sal farmaceuticamente aceitável do mesmo, pelo qual o sujeito experimenta uma resposta terapêutica.
BR112022022932A 2020-05-11 2021-05-10 Inibidor de vcp/p97 para o tratamento do câncer BR112022022932A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023120P 2020-05-11 2020-05-11
US202063114435P 2020-11-16 2020-11-16
PCT/US2021/031622 WO2021231323A1 (en) 2020-05-11 2021-05-10 Vcp/p97 inhibitor for the treatment of cancer

Publications (1)

Publication Number Publication Date
BR112022022932A2 true BR112022022932A2 (pt) 2023-02-23

Family

ID=78524882

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022932A BR112022022932A2 (pt) 2020-05-11 2021-05-10 Inibidor de vcp/p97 para o tratamento do câncer

Country Status (10)

Country Link
US (1) US20230172936A1 (pt)
EP (1) EP4149943A4 (pt)
JP (1) JP2023526223A (pt)
CN (1) CN115916779A (pt)
AU (1) AU2021271627A1 (pt)
BR (1) BR112022022932A2 (pt)
CA (1) CA3177969A1 (pt)
MX (1) MX2022014290A (pt)
TW (1) TW202207938A (pt)
WO (1) WO2021231323A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240097859A (ko) * 2021-11-10 2024-06-27 카시 파마슈티컬스, 인코포레이티드 암의 치료용 VCP/p97 억제제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527831T3 (es) * 2009-09-23 2015-01-30 Glaxosmithkline Llc Combinación que comprende el inhibidor de MEK: N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido[4,3-d]pirimidin-1-il]fenil}acetamida y el inhibidor de Akt: N-{(1S)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1H-pirazol-5-il)-2-tiofenocarboxamida
US20130165456A1 (en) * 2010-08-26 2013-06-27 Tona M. Gilmer Combination
US9868722B2 (en) * 2013-12-10 2018-01-16 Cleave Biosciences, Inc. Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex
JP6387111B2 (ja) * 2014-01-20 2018-09-05 クリーブ バイオサイエンシズ インコーポレイテッド ｐ９７複合体の阻害剤としての縮合ピリミジン
US20170267679A1 (en) * 2016-03-15 2017-09-21 Cleave Biosciences, Inc. TRICYCLIC FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF p97 COMPLEX

Also Published As

Publication number Publication date
WO2021231323A1 (en) 2021-11-18
AU2021271627A1 (en) 2022-12-15
JP2023526223A (ja) 2023-06-21
CA3177969A1 (en) 2021-11-18
EP4149943A4 (en) 2024-06-05
MX2022014290A (es) 2023-02-09
EP4149943A1 (en) 2023-03-22
TW202207938A (zh) 2022-03-01
CN115916779A (zh) 2023-04-04
US20230172936A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
PH12020551315A1 (en) Benzoxazepin oxazolidinone compounds and methods of use
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023007192A (es) Inhibidores de prmt5.
PH12021500017A1 (en) Pyrazolo [3,4-b]pyridine compounds as inhibitors of tam and met kinases
PH12018500532A1 (en) 8-[6-[3-(amino)propoxy]-3-pyridyl]-1-isopropyl-imidazo[4,5-c]quinolin-2- one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
SA520412192B1 (ar) مشتقات 5-(2-(2، 5-داي فلورو فنيل)بيروليدين-1-يل) -3-(1h-بيرازول-1-يل) بيرازولو[1، 5-a] بيريميدين والمركبات ذات الصلة كمثبطات كيناز trk لعلاج السرطان
NZ591712A (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
ME00142B (me) Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze
BRPI0413452A (pt) composto, composição farmacêutica, kit, artigo de fabricação, e, métodos de inibir dpp-iv, terapêutico e de tratar um estado de doença, cáncer, distúrbios autoimunes, uma condição einfecção por hiv
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
MX2022012285A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
EA201891050A1 (ru) Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
WO2018102687A3 (en) Combination therapy for treating cancer
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
NZ703152A (en) Dosing regimen for janus kinase (jak) inhibitors
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
CA3173678A1 (en) Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
BR112022022932A2 (pt) Inibidor de vcp/p97 para o tratamento do câncer
MX2021013942A (es) Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton.
BR112022000734A2 (pt) Método para tratar câncer em um paciente, uso de composto 1, e, composto 1
MX2022006180A (es) Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.